Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: Circadian variance, effects of treatment, and relationship to parathyroid status

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 11, 2010, Pages

  Carpenter, Thomas O ^a   Insogna, Karl L ^a   Zhang, Jane H ^b   Ellis, Bruce ^a   Nieman, Sherril ^a   Simpson, Christine ^a   Olear, Elizabeth ^a   Gundberg, Caren M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PARATHYROID HORMONE; PHOSPHATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GROUPS BY AGE; HUMAN; MALE; PARATHYROID FUNCTION; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SCHOOL CHILD; THERAPY EFFECT; TREATMENT RESPONSE; X LINKED HYPOPHOSPHATEMIC RICKETS;

EID: 78049511826     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0589     Document Type: Article

References (14)

1. Carpenter TO, Drezner M 2007 Primary disorders of phosphate metabolism. In: Arnold A, section ed. (www.endotext.org, version of September 10, 2007). South Dartmouth, MA: mdtext.com, inc.
2. Carpenter TO, Mitnick MA, Ellison A, Smith C, Insogna KL 1994 Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia. J Clin Endocrinol Metab 78:1378-1383
3. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663 (Pubitemid 36459471)
4. Carpenter TO 2003 Oncogenic osteomalacia - a complex dance of factors. N Engl J Med 348:1705-1708
5. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ 2001 Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079-2086 (Pubitemid 33070451)
6. Brownstein CA, Adler F, Nelson-Williams C, Iijima J, Li P, Imura A, Nabeshima Y, Reyes-Mugica M, Carpenter TO, Lifton RP 2008 A translocation causing increased α-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci USA 105:3455-3460
7. Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R, Mohammadi M, White KE, Econs MJ 2007 A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 117:2684-2691
8. Razzaque MS 2009 The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 5:611-619
9. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T 2006 Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774
10. Ardeshirpour L, Cole DE, Carpenter TO 2007 Evaluation of bone and mineral disorders. Pediatr Endocrinol Rev 5(Suppl 1):584-598
11. Galitzer H, Ben-Dov I, Lavi-Moshayoff V, Naveh-Many T, Silver J 2008 Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secretion. Curr Opin Nephrol Hypertens 17:363-367
12. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T 2010 Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 77:211-218
13. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M 2005 Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205-2215
14. Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ 2010 Treatment of XLH with calcitriol and phosphate increases circulating FGF23 concentrations. J Clin Endocrinol Metab 95:1846-1850